title: Resveratrol attenuates cisplatin-induced nephrotoxicity in rats.
abstract: Cisplatin is an antitumor drug widely used in the treatment of many malignant tumors. However, the most common adverse effect, nephrotoxicity, limits the use of this drug in many cancer patients. Resveratrol is a phytoalexin that presents highly efficient protection in experimental nephrotoxicity models. This study evaluated the effect of resveratrol on cisplatin-induced kidney damage. Male Wistar rats were treated with resveratrol (25 mg/kg b.w., i.p.) before the administration of cisplatin (5 mg/kg b.w., i.p.) and killed 2 or 5 days later. Blood and urine samples were collected and the kidneys were removed. Rats from the cisplatin group showed acute tubular cell necrosis and increased immunostaining for ED1 (macrophages/monocytes) and T-lymphocytes in the renal cortex and outer medulla when compared with the control group. These alterations were less intense in animals pre-treated with resveratrol. Moreover, indicators of renal injury such as increased serum creatinine levels, urinary volume and urinary protein caused by the administration of cisplatin, were also significantly reduced with resveratrol. Increased lipid peroxidation and glutathione depletion in tissue were attenuated by resveratrol. In conclusion, resveratrol attenuated the cisplatin-induced structural and functional renal changes by reducing free radicals and inhibiting inflammatory cell infiltrates.
authors.affiliation: Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. Do Café, s/n, 14041-903 Ribeirao Preto, Brazil. caamaral@fcfrp.usp.br
authors.forename: Cátia Lira
authors.initials: CL
authors.lastname: Do Amaral
authors.forename: Heloísa Della Coletta
authors.initials: HD
authors.lastname: Francescato
authors.forename: Terezila Machado
authors.initials: TM
authors.lastname: Coimbra
authors.forename: Roberto Silva
authors.initials: RS
authors.lastname: Costa
authors.forename: Joana D'arc Castania
authors.initials: JD
authors.lastname: Darin
authors.forename: Lusânia Maria Greggi
authors.initials: LM
authors.lastname: Antunes
authors.forename: Maria De Lourdes Pires
authors.initials: Mde L
authors.lastname: Bianchi
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D000975:Antioxidants / Q000494:pharmacology*; D002945:Cisplatin / Q000633:toxicity*; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D053331:Ectodysplasins / Q000378:metabolism; D007683:Kidney Tubular Necrosis, Acute / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D007684:Kidney Tubules / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D011507:Proteinuria / Q000139:chemically induced / Q000652:urine; D051381:Rats; D017208:Rats, Wistar; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D014554:Urination / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D053331:Ectodysplasins; D013267:Stilbenes; D003404:Creatinine; D002945:Cisplatin; D000077185:Resveratrol